Influenza Vaccine Development

Print

email this

The DHVI Influenza program is committed to finding a safe and effective broadly reactive vaccine for all influenza strains, including pandemic influenza.  DHVI Investigators who are part of this effort include Drs. Larry Liao, Elizabeth Ramsburg, and Barton Haynes.  Influenza is one of the most common infections worldwide.  Because of the ability of influenza viruses to mutate each year and because influenza vaccination and infection induces predominantly strain-specific hemagglutinin (HA) neutralizing antibodies, it is necessary to develop a yearly vaccine based on circulating influenza strains. Furthermore, because of some lethal strains that live in birds in (avian influenza), the risk of a global lethal pandemic flu remains high. Thus, a goal of DHVI Influenza program is to find a safe and effective broadly reactive or “universal” vaccine for all influenza strains, including pandemic influenza.